The imitator of immune-tolerant chronic hepatitis B: A killer in disguise

키워드

참고문헌 (20)

1. Jun Sik Yoon, "Hepatocellular Carcinoma in Korea: an Analysis of the 2015 Korean Nationwide Cancer Registry", Journal of Liver Cancer, 21(1), pp.58~68 (2021), 대한간암학회[DOI]
2. Sarin SK, "Asian-Pacific clinical practice guidelines on the management of hepatitis B : a 2015 update", Hepatol Int, 10, pp.1~98 (2016)
3. The Korean Association for the Study of the Liver, "KASL clinical practice guidelines for management of chronic hepatitis B", Clinical and Molecular Hepatology, 28(2), pp.276~331 (2022), 대한간학회
4. Terrault NA, "Update on prevention, diagnosis, and treatment of chronic hepatitis B : AASLD 2018 hepatitis B guidance", Hepatology, 67, pp.1560~1599 (2018)
5. European Association for the Study of the Liver, "EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection", J Hepatol, 67, pp.370~398 (2017)
6. Nguyen MH, "Histological disease in Asian-Americans with chronic hepatitis B, high hepatitis B virus DNA, and normal alanine aminotransferase levels", Am J Gastroenterol, 104, pp.2206~2213 (2009)
7. Wong GL, "Clinical factors associated with liver stiffness in hepatitis B e antigen-positive chronic hepatitis B patients", Clin Gastroenterol Hepatol, 7, pp.227~233 (2009)
8. Jeong-Ju Yoo, "Long-term prognosis and the need for histologic assessment of chronic hepatitis B in the serological immune-tolerant phase", Clinical and Molecular Hepatology, 29(2), pp.482~495 (2023), 대한간학회
9. Song BC, "Hepatitis B virus genotypes in Korea : an endemic area of hepatitis B virus infection", Intervirology, 48, pp.133~137 (2005)
10. Kim GA, "High risk of hepatocellular carcinoma and death in patients with immune-tolerant-phase chronic hepatitis B", Gut, 67, pp.945~952 (2018)
11. Lee HA, "Comparable outcomes between immune-tolerant and active phases in noncirrhotic chronic hepatitis B : a meta-analysis", Hepatol Commun, 7, pp.e0011~ (2023)
12. Mi Young Jeon, "Negligible risks of hepatocellular carcinoma during biomarker-defined immune-tolerant phase for patients with chronic hepatitis B", Clinical and Molecular Hepatology, 27(2), pp.295~304 (2021), 대한간학회[DOI]
13. Kim GA, "Moderate levels of serum hepatitis B virus DNA are associated with the highest risk of hepatocellular carcinoma in chronic hepatitis B patients", Aliment Pharmacol Ther, 51, pp.1169~1179 (2020)
14. Yang HI, "Risk estimation for hepatocellular carcinoma in chronic hepatitis B (REACH-B): development and validation of a predictive score", Lancet Oncol, 12, pp.568~574 (2011)
15. Tu T, "Hepatitis B Virus DNA integration : In vitro models for investigating viral pathogenesis and persistence", Viruses, 13, pp.180~ (2021)
16. Chan HL, "Effects of tenofovir disoproxil fumarate in hepatitis B e antigenpositive patients with normal levels of alanine aminotransferase and high levels of hepatitis B virus DNA", Gastroenterology, 146, pp.1240~1248 (2014)
17. Chang Y, "Nucleos(t)ide analogue treatment for patients with hepatitis B virus(HBV)e antigen-positive chronic HBV genotype C infection : A nationwide, multicenter, retrospective study", J Infect Dis, 216, pp.1407~1414 (2017)
18. Park ES, "Identification of a quadruple mutation that confers tenofovir resistance in chronic hepatitis B patients", J Hepatol, 70, pp.1093~1102 (2019)
19. Suzuki K, "Effect of switching from tenofovir disoproxil fumarate to tenofovir alafenamide on lipid profiles in patients with hepatitis B", PLoS One, 17, pp.e0261760~ (2022)
20. Lee DH, "Association of chronic hepatitis B infection and antiviral treatment with the development of the extrahepatic malignancies : A nationwide cohort study", J Clin Oncol, 40, pp.3394~3405 (2022)

관련 논문AI추천